Table 2. Treatments, duration, costs and costs per SVR of HCV treatments over time in Switzerland and the US (Table A in S1 File).
| Treatment | Study | Treatment duration, weeks | Patients, n SVR achieved/n total | SVR, % | Swiss Costs USD | Costs per SVR in Switzerland USD | US costs USD | US costs per SVR in US USD |
|---|---|---|---|---|---|---|---|---|
| Step 1 | ||||||||
| IFN-α-2a | FDA Roferon label[29] | 48 | 20/173 | 11.56% | 9,544 | 82,561 | 6,148 | 53,183 |
| IFN-α-2b | Reference[4] | 48 | 37/303 | 12.21% | 9,706 | 79,492 | 6,046 | 49,517 |
| Step 2 | ||||||||
| IFN-α-2b+RBV | CARRY FORWARD[30] | 48 | 111/328 | 33.84% | 23,799 | 70,328 | 25,543 | 75,482 |
| IFN-α-2a+RBV | NV15801[31] | 48 | 100/285 | 35.09% | 20,951 | 59,706 | 24,584 | 70,060 |
| Step 3 | ||||||||
| pegIFN-α-2a+RBV | ADVANCE[6] | 48 | 158/361 | 43.77% | 34,575 | 78,992 | 37,222 | 85,040 |
| pegIFN-α-2a+RBV | NV15801[31] | 48 | 132/298 | 44.30% | 34,575 | 78,047 | 37,222 | 84,023 |
| pegIFN-α-2b+RBV | CARRY FORWARD[30] | 48 | 58/122 | 47.54% | 33,637 | 70,755 | 32,979 | 69,371 |
| pegIFN-α-2a+RBV | QUEST-1[13] | 48 | 65/130 | 50.00% | 34,575 | 69,150 | 37,222 | 74,444 |
| pegIFN-α-2a+RBV | QUEST-2[14] | 48 | 67/134 | 50.00% | 34,575 | 69,150 | 37,222 | 74,444 |
| pegIFN-α-2a+RBV | NV15942[31] | 48 | 142/271 | 52.40% | 34,575 | 65,983 | 37,222 | 71,034 |
| Step 4 | ||||||||
| BOC+ pegIFN-α-2a+RBV | SPRINT-2[7] | 4+44 (73%)* | 233/368 | 63.32% | 42,566 | 67,224 | 57,741 | 91,189 |
| TVR+ pegIFN-α-2a+RBV | OPTIMIZE[32] | 12+36 (67%)† | 270/371 | 72.78% | 47,304 | 64,996 | 75,210 | 103,339 |
| TVR+ pegIFN-α-2a+RBV | OPTMIZE[32] | 12+36 (69%)† | 274/369 | 74.25% | 47,091 | 63,422 | 74,818 | 100,765 |
| TVR+ pegIFN-α-2a+RBV | ADVANCE[6] | 12+36 (68%)† | 285/363 | 78.51% | 47,240 | 60,171 | 75,092 | 95,646 |
| SMV+ pegIFN-α+RBV | QUEST-1[13] | 12+12 (85%)¶ | 210/264 | 79.55% | 44,833 | 56,358 | 85,891 | 107,971 |
| SMV+ pegIFN-α+RBV | QUEST-2[14] | 12+12 (91%)¶ | 209/257 | 81.32% | 44,512 | 54,737 | 87,741 | 107,896 |
| Step 5 | ||||||||
| SOF+ pegIFN-α-2a+RBV | NEUTRINO[11] | 12 | 262/292 | 89.73% | 62,955 | 70,160 | 93,808 | 104,545 |
| SOF/LDV | ION-3[10] | 12 | 208/216 | 96.30% | 62,363 | 64,759 | 94,500 | 98,131 |
| PTV/r/OBV+DSV+ RBV | SAPHIRE-I[12] | 12 | 455/473 | 96.19% | 63,946 | 66,479 | 86,215 | 89,630 |
| PTV/r/OBV+DSV+ RBV | PEARL-IV[9] | 12 | 97/100 | 97.00% | 63,946 | 65,924 | 86,215 | 88,881 |
| SOF/LDV | ION-1[33] | 12 | 210/213 | 98.59% | 62,363 | 63,255 | 94,500 | 95,852 |
| PTV/r/OBV+DSV | PEARL-III[9] | 12 | 209/209 | 100% | 61,956 | 61,956 | 83,319 | 83,319 |
* The stopping rule for response-guided therapy BOC included patients with undetectable HCV RNA from treatment weeks 8 to 24
† A patient qualified for a shortened TVR therapy duration for HCV RNA <25 IU/ml at weeks 4 and 12.
¶ SMV response-guided therapy involved stopping the treatment after 24 weeks for patients with HCV RNA <25 IU/ml at week 4 (undetectable or detectable) and <25 IU/ml at week 12 (undetectable)